Literature DB >> 1294746

Interrater reliability of the tender point criterion for fibromyalgia.

A Cott1, W Parkinson, M J Bell, J Adachi, M Bédard, A Cividino, W Bensen.   

Abstract

The diagnosis fibromyalgia (FS) requires the existence of tender points, routinely identified by clinical examination. We evaluated the interrater reliability of digital (thumb) examination for tender points by comparison with dolorimeter examination, a procedure considered to measure accurately muscle tenderness. Subjects were 15 patients with varying rheumatological diagnoses and anatomically widespread pain. In a physician blinded procedure, 2 rheumatologists determined the tender point count by digital examination at 18 points, and the tender point threshold by dolorimeter at 12 points. A pain threshold of 4 kg/1.77 cm2 or less defined the presence of tender points under both methods. Results indicate (1) classification as FS vs other diagnosis using pain complaint and digital examination for tender points, was moderately reliable (kappa = 0.74, p < 0.005); (2) interrater agreement about presence/absence of tenderness at individual points was not significantly lowered by digital examination (kappa = 0.51, p < 0.0001) relative to dolorimetry (kappa = 0.62, p < 0.0001); however, (3) analyses on the 12 anatomical points that were common to both methods indicated that digital examination resulted in significantly more anatomical points being considered tender relative to dolorimetry. Our findings indicate that digital and dolorimeter measures are equally reliable, but have poor concurrent validity for defining tender points in FS. Implications of these findings for the classification of fibromyalgia are discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1294746

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression.

Authors:  K Fassbender; W Samborsky; M Kellner; W Müller; S Lautenbacher
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Dehydration and symptoms of delayed-onset muscle soreness in hyperthermic males.

Authors:  Michelle A Cleary; Lori A Sweeney; Zebulon V Kendrick; Michael R Sitler
Journal:  J Athl Train       Date:  2005 Oct-Dec       Impact factor: 2.860

3.  Dehydration and symptoms of delayed-onset muscle soreness in normothermic men.

Authors:  Michelle A Cleary; Michael R Sitler; Zebulon V Kendrick
Journal:  J Athl Train       Date:  2006 Jan-Mar       Impact factor: 2.860

4.  Tender point count and total myalgic score in fibromyalgia: changes over a 28-day period.

Authors:  J G McVeigh; M B Finch; D A Hurley; J R Basford; J Sim; G D Baxter
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

Review 5.  Fibromyalgia: A Critical and Comprehensive Review.

Authors:  Andrea T Borchers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

6.  The clinical concept of fibromyalgia as a changing paradigm in the past 20 years.

Authors:  Mary-Ann Fitzcharles; Muhammad B Yunus
Journal:  Pain Res Treat       Date:  2011-10-29

7.  Characterization of migraineurs presenting interictal widespread pressure hyperalgesia identified using a tender point count: a cross-sectional study.

Authors:  Toshihide Toriyama; Tetsuyoshi Horiuchi; Kazuhiro Hongo
Journal:  J Headache Pain       Date:  2017-12-28       Impact factor: 7.277

8.  Concurrent validation of a pressure pain threshold scale for individuals with myofascial pain syndrome and fibromyalgia.

Authors:  Scott W Cheatham; Morey J Kolber; G Monique Mokha; William J Hanney
Journal:  J Man Manip Ther       Date:  2017-07-09

9.  Reproducibility of tender point examination in chronic low back pain patients as measured by intrarater and inter-rater reliability and agreement: a validation study.

Authors:  Ole Kudsk Jensen; Jacob Callesen; Merete Graakjaer Nielsen; Torkell Ellingsen
Journal:  BMJ Open       Date:  2013-02-26       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.